<DOC>
	<DOCNO>NCT02578888</DOCNO>
	<brief_summary>This randomize clinical trial study palliative care program improving quality life patient high-risk gynecologic malignancy original first tumor body ( primary ) come back ( recurrent ) . Palliative care care give patient family face problem associate life-threatening illness , prevention relief suffer mean early identification impeccable assessment treatment pain problem , physical , psychosocial spiritual . Studying palliative care program may help doctor learn patient quality life , use healthcare service , relief pain .</brief_summary>
	<brief_title>Palliative Care Improving Quality Life Patients With High Risk Primary Recurrent Gynecologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Validate model proactive palliative medicine referral . II . Quantify impact palliative care aggressive care end-of-life ( PCARE ) versus PCARE + idiographic assessment quality care patient satisfaction . III . Utilizing CMO data Investigators create cost model patient randomize PCARE versus patient refuse randomization . IV . Determine impact proactive model palliative care consultation time diagnosis family/caregivers . OUTLINE : Patients randomize 1 2 arm . GROUP I ( usual PCARE ) : Patients complete European Organization Research Treatment Cancer quality life-30 ( EORTCQLQ-30 ) Family Satisfaction Advanced Cancer Care ( FAMCARE ) questionnaire every 6 week 3 visit . GROUP II : ( usual PCARE + idiographic assessment ) : Patients complete EORTC QLQ-30 , FAMCARE questionnaire Group I undergo idiographic assessment . Beginning within 4 week visit gynecologic oncologist , patient refer outpatient palliative medicine consultation . After completion study , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<criteria>Women primary recurrent diagnosis ovarian , uterine , peritoneal , cervical vulvar cancer follow : &lt; 30 % project 5 year survival base histopathological stage Nonpelvic recurrent malignancy Persistent progressive disease despite primary treatment surgery , chemotherapy Palliative performance scale &lt; 60 Enrollment within 6 week tumor board review</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>